Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Apitherapy: Usage And Experience In German Beekeepers
Apitherapy products enhance the recovery of CCL4-induced hepatic damages in rats
Apitoxin protects rat pups brain from propionic acid-induced oxidative stress: The expression pattern of Bcl-2 and Caspase-3 apoptotic genes
Apitoxin harvest affects population development but not the hygienic behavior of African-derived honey bees
Apitherapeutics and phage-loaded nanofibers as wound dressings with enhanced wound healing and antibacterial activity
Apitoxin Aquapuncture and Administration of Herbal Medicines in a Dog with Superficial Pyoderma
Apium graveolens extract influences mood and cognition in healthy mice
Apium graveolens Extract Inhibits Cell Proliferation and Expression of Vascular Endothelial Growth Factor and Induces Apoptosis in the Human Prostatic Carcinoma Cell Line LNCaP
Apixaban versus enoxaparin in patients with total knee arthroplasty A meta-analysis of randomised trials
Apixaban in Patients with Atrial Fibrillation
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials
Apixaban in Acute Coronary Syndromes
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups
Apixaban reduced recurrence and did not increase major bleeding in previously treated VTE
Apixaban reduced stroke or systemic embolism in AF more than warfarin regardless of type or duration of AF
Apixaban (Eliquis) for Stroke Prevention in Atrial Fibrillation
Apixaban for Extended Treatment of Venous Thromboembolism
Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Implications of Time in Therapeutic Range
Apixaban, sodium picosulfate, and regorafenib
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
Apixaban and Rivaroxaban Decrease Deep Venous Thrombosis But Not Other Complications After Total Hip and Total Knee Arthroplasty
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)
Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes Insights From the APPRAISE-2 Trial
Apixaban is Dear to Me, but Dearer Still is Warfarin
Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Apixaban to prevent venous thromboembolism after knee replacement
Apixaban: an emerging oral factor Xa inhibitor
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
Apixaban: A novel oral inhibitor of factor Xa
Apixaban Versus Enoxaparin in Elective Major Orthopedic Surgery: A Clinical Review
Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty: A Meta-Analysis
Apixaban: A New Player in the Anticoagulant Class
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Apixaban First Global Approval
Apixaban
Apixaban after Acute Coronary Syndrome
Apixaban: an Oral Direct Factor-Xa Inhibitor
Apixaban A Review of its Use in the Prevention of Venous Thromboembolism After Knee or Hip Replacement Surgery
Apixaban
Apixaban: A Review of its Use for Reducing the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
Apixaban: An orally active factor Xa inhibitor to prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement POOLED ANALYSIS OF MAJOR VENOUS THROMBOEMBOLISM AND BLEEDING IN 8464 PATIENTS FROM THE ADVANCE-2 AND ADVANCE-3 TRIALS
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Apixaban reduced stroke and systemic embolism compared with warfarin in atrial fibrillation
Apixaban reduced stroke and systemic embolism compared with aspirin in adults with AF for whom VKA therapy was unsuitable
Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis
Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system
Apixaban after Acute Coronary Syndrome REPLY
Apixaban versus Warfarin in Atrial Fibrillation REPLY
Apixaban Dosing in Chronic Kidney Disease Differences Between US and EU Labeling
Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement
Apixaban as therapeutic option in nephropathy patients with heparin induced thrombocytopenia (HIT)
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
Apixaban for the treatment of cerebral venous thrombosis: A case series
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis
Apixaban in atrial fibrillation: does predicted risk matter?
Apixaban versus Warfarin in Atrial Fibrillation
Apixaban Use Among Patients With Severe Renal Impairment
Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function
Apixaban vs. Enoxaparin after Hip Replacement
Apixaban vs. Enoxaparin after Hip Replacement REPLY
Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine
Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients